Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news